<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Polypid — News on 6ix</title>
<link>https://6ix.com/company/polypid</link>
<description>Latest news and press releases for Polypid on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 13 Apr 2026 13:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/polypid" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b34f78dffbe2df112961.webp</url>
<title>Polypid</title>
<link>https://6ix.com/company/polypid</link>
</image>
<item>
<title>PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026</title>
<link>https://6ix.com/company/polypid/news/polypid-to-present-new-phase-3-shield-ii-data-demonstrating-d-plex-sustained-local-release-at-escmid-global-2026</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypid-to-present-new-phase-3-shield-ii-data-demonstrating-d-plex-sustained-local-release-at-escmid-global-2026</guid>
<pubDate>Mon, 13 Apr 2026 13:15:00 GMT</pubDate>
<description>Analysis demonstrates D-PLEX₁₀₀ prolonged delivery mechanism ability to deliver continuous release of doxycycline for 30 days at the surgical incision sitePETACH TIKVA, Israel, April 13, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that the Company will present new pharmacokinetic data from the Phase 3</description>
</item>
<item>
<title>PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA</title>
<link>https://6ix.com/company/polypid/news/polypid-initiates-d-plex-nda-submission-to-the-fda</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypid-initiates-d-plex-nda-submission-to-the-fda</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on</description>
</item>
<item>
<title>PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application</title>
<link>https://6ix.com/company/polypid/news/polypid-receives-pdufa-fee-waiver-from-fda-for-d-plexs-new-drug-application</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypid-receives-pdufa-fee-waiver-from-fda-for-d-plexs-new-drug-application</guid>
<pubDate>Tue, 17 Mar 2026 12:30:00 GMT</pubDate>
<description>FDA Grants $4.3 Million Small Business Waiver, Enabling Focus on Commercialization Preparations Company On Track to Initiate NDA Submission by the End of this Month PETACH TIKVA, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that the U.S. Food and Drug Administration (FDA) has granted</description>
</item>
<item>
<title>PolyPid Announces Participation in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/polypid/news/polypid-announces-participation-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypid-announces-participation-in-upcoming-investor-conferences</guid>
<pubDate>Wed, 25 Feb 2026 13:35:00 GMT</pubDate>
<description>PETACH TIKVA, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in two upcoming investor conferences taking place during March 2026. Citizens 2026 Life Sciences Conference Date: March 10, 2026 at 1:40 pm ETLocation: Eden Roc Miami Beach, Miami Beach,</description>
</item>
<item>
<title>PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/polypid/news/polypid-provides-corporate-reports-fourth-123000051</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypid-provides-corporate-reports-fourth-123000051</guid>
<pubDate>Wed, 11 Feb 2026 12:30:00 GMT</pubDate>
<description>The Company is in Advanced Stages of Commercial U.S. Partnership Discussions for D-PLEX₁₀₀ Positive FDA Pre-NDA Feedback Supports Rolling NDA Review; Submission Expected to Begin by the End of the First Quarter of 2026 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness,</description>
</item>
<item>
<title>PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026</title>
<link>https://6ix.com/company/polypid/news/polypid-report-fourth-quarter-2025-130000404</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypid-report-fourth-quarter-2025-130000404</guid>
<pubDate>Wed, 28 Jan 2026 13:00:00 GMT</pubDate>
<description>PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business o</description>
</item>
<item>
<title>PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors</title>
<link>https://6ix.com/company/polypid/news/polypid-appoints-veteran-medtech-leader-133000680</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypid-appoints-veteran-medtech-leader-133000680</guid>
<pubDate>Tue, 16 Dec 2025 13:30:00 GMT</pubDate>
<description>Appointment Enhances PolyPid’s Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application SubmissionPETACH TIKVA, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors, effective as of December 11, 2025. “Brooke’s appointment marks an exciting and pivotal moment for P</description>
</item>
<item>
<title>PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission</title>
<link>https://6ix.com/company/polypid/news/polypid-announces-positive-fda-pre-133000084</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypid-announces-positive-fda-pre-133000084</guid>
<pubDate>Wed, 03 Dec 2025 13:30:00 GMT</pubDate>
<description>NDA to be Submitted on a Rolling Basis, Beginning Early 2026PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a formal pre-New Drug Application (“NDA”) meeting minutes from the U.S. Food and Drug Administration (“FDA”) supporting the NDA submission of D-PLEX100, the Company’s lead product candidate for the prevention of surgical</description>
</item>
<item>
<title>PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025</title>
<link>https://6ix.com/company/polypid/news/polypid-participate-roth-capital-partners-133000633</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypid-participate-roth-capital-partners-133000633</guid>
<pubDate>Tue, 25 Nov 2025 13:30:00 GMT</pubDate>
<description>Internationally recognized colorectal surgeon Steven D. Wexner, MD, FACS, FRCS, to discuss the clinical and economic burden of surgical site infections and the therapeutic potential of D-PLEX₁₀₀PETACH TIKVA, Israel, Nov. 25, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will participate in a virtual Key Opinion Leader (KOL) event hosted by ROTH Capital Partners. KOL Ev</description>
</item>
<item>
<title>PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/polypid/news/polypid-provides-corporate-reports-third-123000213</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypid-provides-corporate-reports-third-123000213</guid>
<pubDate>Wed, 12 Nov 2025 12:30:00 GMT</pubDate>
<description>Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive Phase 3 Trial Results Company Continues to Advance Towards Commercial Manufacturing Readiness with Successful Completion of IMOH GMP Inspection Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Co</description>
</item>
<item>
<title>PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"</title>
<link>https://6ix.com/company/polypid/news/polypids-d-plex-wins-biotech-133000812</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypids-d-plex-wins-biotech-133000812</guid>
<pubDate>Thu, 06 Nov 2025 13:30:00 GMT</pubDate>
<description>PolyPid's Lead Candidate Recognized for Addressing Critical Unmet Need in Surgical Site Infection Prevention Following Positive Phase 3 ResultsPETACH TIKVA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company focused on improving surgical outcomes, today announced that D-PLEX₁₀₀, the company’s lead candidate, has been named "Therapeutics Solution of the Year" by BioTech Breakthrough, a leading independent market intel</description>
</item>
<item>
<title>PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025</title>
<link>https://6ix.com/company/polypid/news/polypid-report-third-quarter-2025-123000139</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypid-report-third-quarter-2025-123000139</guid>
<pubDate>Wed, 29 Oct 2025 12:30:00 GMT</pubDate>
<description>PETACH TIKVA, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 12, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business op</description>
</item>
<item>
<title>PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress</title>
<link>https://6ix.com/company/polypid/news/polypid-present-positive-phase-3-124500882</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypid-present-positive-phase-3-124500882</guid>
<pubDate>Tue, 30 Sep 2025 12:45:00 GMT</pubDate>
<description>The Company will present the reported topline results from its phase 3 SHIELD II trial at one of the world’s leading surgical conferencesPETACH TIKVA, Israel, Sept. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dr. Shmuel Sharoni will present the topline results from the Company's successful Phase 3 SHIELD II trial of D-PLEX₁₀₀ at the upcoming 2025 American College of</description>
</item>
<item>
<title>PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference</title>
<link>https://6ix.com/company/polypid/news/polypid-present-lytham-partners-fall-124400411</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypid-present-lytham-partners-fall-124400411</guid>
<pubDate>Wed, 17 Sep 2025 12:44:00 GMT</pubDate>
<description>PETACH TIKVA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that management will be presenting at the Lytham Partners Fall 2025 Virtual Investor Conference on September 30, 2025. Additionally, management will be participating in the upcoming 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025. Lytham Partners Fall 2025 Investor Conference,</description>
</item>
<item>
<title>PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀</title>
<link>https://6ix.com/company/polypid/news/polypid-successfully-completes-israeli-ministry-123000038</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypid-successfully-completes-israeli-ministry-123000038</guid>
<pubDate>Tue, 16 Sep 2025 12:30:00 GMT</pubDate>
<description>Key Manufacturing Milestone Strengthens PolyPid’s Position as it Advances Towards Global Commercialization of D-PLEX₁₀₀ Following Successful SHIELD II Phase 3 TrialPETACH TIKVA, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the successful completion of a routine Good Manufacturing Practice (GMP) inspection by the Israeli Ministry of Health. The inspection, co</description>
</item>
<item>
<title>PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference</title>
<link>https://6ix.com/company/polypid/news/polypid-participate-upcoming-27th-annual-123000706</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypid-participate-upcoming-27th-annual-123000706</guid>
<pubDate>Wed, 03 Sep 2025 12:30:00 GMT</pubDate>
<description>PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that senior management will participate in the upcoming 27th Annual H.C. Wainwright Global Investment Conference taking place on September 8-9, 2025, at the Lotte New York Palace Hotel, New York City. PolyPid's fireside chat with H.C. Wainwright Managing Director, Equity Research, Brandon Folkes, wil</description>
</item>
<item>
<title>PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference</title>
<link>https://6ix.com/company/polypid/news/polypid-present-14th-meeting-israel-123000320</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypid-present-14th-meeting-israel-123000320</guid>
<pubDate>Tue, 02 Sep 2025 12:30:00 GMT</pubDate>
<description>PETACH TIKVA, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dalit Hazan, Deputy CEO, EVP R&D, Clinical, and Regulatory Affairs, will present at the 14th meeting of the Israel Controlled Release Society (ICRS) Conference taking place at the Enjoy Hotel, Dead Sea, in Israel from September 7-9, 2025. The presentation, titled "Novel Local Prolonged Drug Deli</description>
</item>
<item>
<title>PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/polypid/news/polypid-provides-corporate-reports-second-113000035</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypid-provides-corporate-reports-second-113000035</guid>
<pubDate>Wed, 13 Aug 2025 11:30:00 GMT</pubDate>
<description>Positive Phase 3 SHIELD II Trial Results - D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI NDA submission expected in Q1 2026 Unveiled a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Obesity and Diabetes Market Successful Warrant Exercise Significantly Strengthened Balance Sheet with Cash Runway into 2026 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasd</description>
</item>
<item>
<title>PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer</title>
<link>https://6ix.com/company/polypid/news/polypid-appoints-dr-nurit-tweezer-120000060</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypid-appoints-dr-nurit-tweezer-120000060</guid>
<pubDate>Tue, 12 Aug 2025 12:00:00 GMT</pubDate>
<description>Dr. Tweezer-Zaks Transitions from the Company’s Board of Directors to Lead Medical Strategy Following Positive Phase 3 Results and Expanding PipelinePETACH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Dr. Nurit Tweezer-Zaks, M.D., M.B.A., as Chief Medical Officer, effective as of August 18, 2025. Dr. Tweezer-Zaks, who has served on P</description>
</item>
<item>
<title>PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025</title>
<link>https://6ix.com/company/polypid/news/polypid-report-second-quarter-2025-120000727</link>
<guid isPermaLink="true">https://6ix.com/company/polypid/news/polypid-report-second-quarter-2025-120000727</guid>
<pubDate>Wed, 30 Jul 2025 12:00:00 GMT</pubDate>
<description>PETACH TIKVA, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business ope</description>
</item>
</channel>
</rss>